Treatment Strategies in ctDNA-Positive CRC
Panelists discuss how treatment strategies for circulating tumor DNA (ctDNA)–positive colorectal cancer (CRC) are evolving, with a focus on tailoring interventions based on molecular findings to improve patient outcomes and minimize unnecessary therapies.
Video Player is loading.
EP: 1.Colorectal Cancer: Rising Prevalence and the Promise of ctDNA
EP: 2.ctDNA in CRC Management: Evolving Approaches for Personalized Care
EP: 3.MRD Detection in CRC: Guiding Postsurgical Treatment Decisions and Monitoring
EP: 4.MRD Testing in CRC: Optimizing Chemo-Sparing Strategies and Residual Disease Control
EP: 5.DYNAMIC: ctDNA-Guided Therapy on Adjuvant Chemotherapy Decisions in Stage II Colon Cancer
EP: 6.ctDNA Insights From INTERCEPT, BESPOKE, COSMOS-CRC-01, and GALAXY Studies
EP: 7.GALAXY Study: ctDNA-Based MRD Monitoring in Resected CRC
EP: 8.GALAXY Study Results: ctDNA Status Predicts Outcomes and Treatment Benefit in CRC
Now Viewing
EP: 9.Treatment Strategies in ctDNA-Positive CRC
EP: 10.GALAXY 24-Month Data from ESMO 2024: MRD Status and ctDNA Clearance Key in CRC
EP: 11.CLM in GALAXY: MRD Predicts Adjuvant Therapy Benefit and Prognosis
Recent Videos
CAR T vs Bispecifics: Expanding CAR T Reach in B-Cell Malignancies
Real-World Use, Outpatient Dosing and Transitions of Care in Academic and Community Settings
A Review of Outpatient Step-Up Dosing for Talquetamab in R/R MM
PERSEUS Trial: MRD Negativity
PERSEUS Trial: Design/Baseline Characteristics
Treatment Overview of Transplant-Eligible Newly Diagnosed Multiple Myeloma
Understanding ICANS Management With CAR T: Low-Grade Events With High Resolution Rates
CEPHEUS Trial: Adverse Events
CRS Management Insights With Liso-Cel: Comprehensive Analysis From Real-World Data in 1579 Patients and Implications for Safe Clinical Practice
Talquetamab in R/R MM: Managing GPRC5D-direced AEs, Prophylaxis, and New Safety Signals
Related Content
